Product Overview

Clofi 100 mg is a prescription medication that contains clomiphene citrate, a selective estrogen receptor modulator widely used in the management of female infertility. Manufactured by Sunrise Remedies Pvt Ltd, each strip contains ten tablets of 100 mg clomiphene, offering a convenient dosing schedule for women seeking ovulation induction. The product is packaged in various strengths, including 60, 120, and 180 tablets, to accommodate different treatment protocols. Clofi is classified under the category of female infertility therapies and is intended for oral administration under medical supervision.

What is Clofi 100 mg (Clomiphene)

Clomiphene citrate functions as a non‑steroidal fertility agent that stimulates the release of gonadotropins from the anterior pituitary gland. By acting as an estrogen receptor antagonist in the hypothalamus, it increases the secretion of follicle‑stimulating hormone (FSH) and luteinizing hormone (LH), promoting follicular development and ovulation in women with ovulatory disorders. The active ingredient, clomiphene, is chemically distinct from other fertility drugs and is recognized by major regulatory bodies such as the FDA and the PubMed database for its proven efficacy in controlled clinical studies.

Uses and Benefits

The primary indication for Clofi 100 mg is the treatment of infertility associated with polycystic ovary syndrome (PCOS), hypothalamic amenorrhea, and other ovulatory dysfunctions. Clinical evidence supports its role in achieving ovulation rates of 70‑80 % and pregnancy rates of 30‑40 % after six treatment cycles when used according to established protocols. Benefits include oral administration, cost‑effectiveness compared with injectable gonadotropins, and a well‑characterized safety profile when monitored by a healthcare professional. Additionally, Clofi can be integrated into assisted reproductive technologies (ART) regimens, providing a flexible option for fertility specialists.

How It Works

Clomiphene citrate exerts its pharmacodynamic effect by binding to estrogen receptors in the hypothalamic neurons, partially antagonizing the negative feedback of endogenous estrogen. This antagonism triggers the release of gonadotropin‑releasing hormone (GnRH), which subsequently stimulates the anterior pituitary to secrete FSH and LH. The rise in gonadotropins promotes the development of multiple ovarian follicles, increasing the likelihood of ovulation. The drug’s long half‑life (approximately 14 hours) allows for once‑daily dosing over a limited treatment window, typically five days per cycle.

Dosage Guidelines

Dosage of Clofi must be individualized based on patient age, ovarian reserve, and response to prior therapy. The standard regimen involves a daily oral dose of 100 mg for five consecutive days, usually initiated on day 3 to day 5 of the menstrual cycle. Subsequent cycles may employ a stepwise increase to 150 mg or a decrease to 50 mg, depending on ovulation response and tolerability. Physicians typically monitor ovarian follicular development via ultrasound and adjust dosage accordingly. It is essential that patients adhere to the prescribed schedule and do not exceed recommended cycles, as prolonged use beyond six months may increase the risk of ovarian hyperstimulation and endometrial hyperplasia.

Side Effects

Like all pharmaceutical agents, Clofi may be associated with adverse effects. Commonly reported side effects include hot flashes, abdominal discomfort, breast tenderness, and mild nausea. Less frequent but clinically significant events comprise visual disturbances, ovarian hyperstimulation syndrome (OHSS), and endometrial thickening. Rarely, patients may experience mood changes or allergic reactions. Individuals experiencing severe abdominal pain, rapid weight gain, or shortness of breath should seek immediate medical attention, as these may signal OHSS. A thorough discussion of potential side effects with a qualified healthcare provider is recommended before initiating therapy.

Warnings and Precautions

Clofi is contraindicated in patients with known hypersensitivity to clomiphene or any component of the formulation, as well as in those with ovarian cysts, liver disease, or abnormal uterine bleeding of unknown origin. Caution is advised in women with a history of thromboembolic disorders, as estrogenic activity may increase thrombotic risk. Concomitant use with other ovulation‑inducing agents should be avoided unless explicitly directed by a fertility specialist. Patients should inform their clinician of any ongoing medications, particularly those that affect hepatic enzymes, to prevent pharmacokinetic interactions. Finally, Clofi is not indicated for use in men or children, and its use during pregnancy is strictly prohibited.

FAQs

1. What is the recommended treatment cycle length for Clofi? The typical protocol involves five days of dosing per cycle, with subsequent cycles spaced approximately one month apart. Most clinicians limit therapy to a maximum of six cycles to balance efficacy and safety.
2. Can Clofi be used alongside other fertility medications? Clofi should not be combined with other ovulation‑inducing agents without medical supervision, as this may increase the risk of multiple gestations or ovarian hyperstimulation.
3. How is ovulation monitored during Clofi treatment? Ovulation is commonly assessed via transvaginal ultrasound to track follicular growth, and may be supplemented with luteinizing hormone (LH) predictor kits.
4. Is Clofi safe for women with polycystic ovary syndrome (PCOS)? Yes, clinical studies have demonstrated its effectiveness in inducing ovulation among women with PCOS, provided that liver function and ovarian status are regularly evaluated.
5. What should I do if I miss a dose? If a scheduled dose is missed, the patient should contact their prescribing physician before taking the medication, as timing can affect ovulation induction.

For additional authoritative information, refer to resources such as the MedlinePlus database, the World Health Organization, and the Drugs.com monograph on clomiphene citrate.

Related Products

• DLX 30 mg (Duloxetine)
• DLX 60 mg (Duloxetine)
• DLX (Duloxetine)
• Grafix Capsules (Herbal)
• Grafix Cream 100 g (Herbal)
• Super Zudena (Udenafil/Dapoxetine)
• Extra Super P Force 100mg (Sildenafil/Dapoxetine)
• Extra Super Tadarise (Tadalafil/Dapoxetine)
• Femalegra 100 mg (Female Viagra)(Sildenafil Citrate)
• Malegra 50 mg (Sildenafil Citrate)
• Malegra Tablet
• Malegra 100 mg (Sildenafil Citrate)